News: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

8.40EUR
19 Sep 2014
Price Change (% chg)

€0.12 (+1.47%)
Prev Close
€8.28
Open
€8.32
Day's High
€8.45
Day's Low
€8.32
Volume
43,637
Avg. Vol
69,620
52-wk High
€10.18
52-wk Low
€6.60

Search Stocks
Select another date:

Fri, Sep 5 2014

BRIEF-Ablynx launches sponsored Level I ADR programme in the U.S.

* Ablynx establishes sponsored Level I ADR programme in the united states

BRIEF-Ablynx signs exclusive license agreement with China's Eddingpharm

* Signs exclusive license agreement with Eddingpharm to develop and commercialise its anti-TNFa Nanobody in greater China

BRIEF-Ablynx posts net loss of 6.3 mln stg

* Raised 41.7 million euro in a private placement of new shares (accelerated book building procedure, abo)

BRIEF-Ablynx says awarded 2.1 mln euros grant by Flemish Agency

* Ablynx : Ablynx awarded EUR 2.1 million grant to support development of novel nanobodies for ocular applications

BRIEF-Ablynx raises 41.7 mln euros through private placement

Announces that it has raised 41,720,822 through a private placement of new shares via an accelerated

BRIEF-Ablynx's anti-vWF nanobody, caplacizumab, achieves clinical proof-of-concept in phase II titan study

* Ablynx's anti-vwf nanobody, caplacizumab, achieves clinical proof-of-concept in phase ii titan study

Belgium's Ablynx increases cash position after Merck payment

BRUSSELS, May 14 - Belgian biotech group Ablynx said its cash reserves increased in the first quarter after an upfront payment from Merck & Co as part of a research deal for immune oncology.

BRIEF-Ablynx posts Q1 net loss 2.8 mln euros

* Anticipated that top-line phase II data from Titan study with Caplacizumab will be reported in June 2014

BRIEF-Ablynx initiates phase I study of anti-il-6R nanobody with Abbvie

* Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie

Select another date:
Search Stocks